Work

Association between bosentan and reduced detection of precapillary pulmonary hypertension in systemic sclerosis: evidence from a EUSTAR study

Year: 2026
Type: article
Abstract: Objectives: To evaluate whether exposure to vasoactive-vasodilating drugs (VVDs), particularly bosentan, is associated with reduced detection of precapillary pulmonary hypertension (PH) in systemic sclerosis (SSc). Design: Post hoc retrospective case-control study. Setting: European Scleroderma Trials and Research database. Participants: SSc patients who underwent their first right heart catheterisation (RHC); patients with postcapillary PH (pulmonary wedge pressure >15 mm Hg) were excluded. Interventions: Exposure to VVDs (endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors, prostanoids) was defined as 'ever' before or 'ongoing' at the time of RHC. Main outcome measures: Presence of precapillary PH at RHC. Results: Among the 944 patients included in the study, 498 (53%) were diagnosed with precapillary PH. Bosentan 'ever' was associated with a lower likelihood of a precapillary PH detection (OR 0.594, 95% CI 0.362 to 0.975) in the whole population. When considering 'ongoing' bosentan exposure, this result was confirmed only in patients with current DU (OR 0.230, 95% CI 0.081 to 0.652). ERAs in general showed a trend for protective effects towards detection of precapillary PH in patients with current DU ('ever': OR 0.636, 95% CI 0.349 to 1.158; 'ongoing': OR 0.435, 95% CI 0.193 to 1.064), while other VVD classes did not. Conclusions: Bosentan, especially when employed in patients with current DU at the time of RHC, was associated with less detection of precapillary PH. These findings highlight the need for individualised treatment strategies and further research to optimise the timing and patient selection for VVD therapy in SSc.
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,150
OpenAlex ID: W7225078153
FWCI:
Cites: 19
Cited by:
Related to: 10